GSK2315698

DRUG4 trials

Sponsors

GlaxoSmithKline

Conditions

Amyloidosis

Phase 1

SAP Depleter Dose Escalation Study in Healthy Volunteers

CompletedNCT01323985

GlaxoSmithKlineAmyloidosis

Start: 2011-01-06End: 2011-06-30Updated: 2017-07-21

SAP Depleter Dose Assessment Study in Patients

CompletedNCT01406314

GlaxoSmithKlineAmyloidosis

Start: 2011-10-13End: 2012-11-14Updated: 2017-06-09

A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis

CompletedNCT01777243

GlaxoSmithKlineAmyloidosis

Start: 2013-05-13End: 2015-12-22Updated: 2018-07-24

Phase 1 Study of GSK2315698 in Healthy Japanese Subjects

CompletedNCT02953808

GlaxoSmithKlineAmyloidosis

Start: 2016-11-30End: 2016-12-31Updated: 2017-01-19

Related Papers

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.

2022-07-095 citations

Updates on Emerging Therapies in Cardiac Light Chain (AL) Amyloidosis

Blood2020-11-041 citations

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

Science Translational Medicine2018-01-03129 citations

Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component

New England Journal of Medicine2015-07-15365 citations